title: MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells.
abstract: Multiple studies have shown that steroid receptor coactivator-3 (SRC-3) is upregulated and promotes cell proliferation in several human cancers, including breast, lung, and prostate carcinoma. However, its molecular determinants remain largely unexplored. In the current study, by way of informatics software, we found that MicroRNA-195 (miR-195) could negatively regulate protein levels of SRC-3 through targeting its 3'-untranslated region (3'-UTR) in hepatocellular carcinoma (HCC) cells. As a result, miR-195 mimics inhibited while its antisense enhanced SRC-3 protein levels. Furthermore, miR-195 could modulate cell proliferation and tumor growth in vivo and in vitro. Therefore, our results demonstrate a novel molecular mechanism for the dysregulated expression of SRC-3 in hepatocellular carcinoma.
authors.affiliation: The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
authors.forename: Hong-Lei
authors.initials: HL
authors.lastname: Jiang
authors.forename: Hao
authors.initials: H
authors.lastname: Yu
authors.forename: Xu
authors.initials: X
authors.lastname: Ma
authors.forename: Dong
authors.initials: D
authors.lastname: Xu
authors.forename: Guo-Fu
authors.initials: GF
authors.lastname: Lin
authors.forename: Dong-Yan
authors.initials: DY
authors.lastname: Ma
authors.forename: Jun-Zhe
authors.initials: JZ
authors.lastname: Jin
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000473:pathology; D049109:Cell Proliferation; D015972:Gene Expression Regulation, Neoplastic; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics* / Q000473:pathology; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D056921:Nuclear Receptor Coactivator 3 / Q000235:genetics* / Q000378:metabolism
chemical_list: C552722:MIRN195 microRNA, human; D035683:MicroRNAs; C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3
references.citation: J Clin Invest. 2012 May;122(5):1869-80
references.pmid: 22505454
references.citation: Onco Targets Ther. 2013 Sep 02;6:1167-78
references.pmid: 24039437
references.citation: Nat Rev Genet. 2013 Aug;14(8):535-48
references.pmid: 23817310
references.citation: Pharmazie. 2012 Jul;67(7):645-51
references.pmid: 22888524
references.citation: Nat Rev Drug Discov. 2013 Nov;12(11):847-65
references.pmid: 24172333
references.citation: Mol Endocrinol. 2010 Jun;24(6):1187-202
references.pmid: 20392877
references.citation: Int J Biol Sci. 2011;7(5):664-72
references.pmid: 21647249
references.citation: Mol Endocrinol. 2003 Sep;17(9):1681-92
references.pmid: 12805412
references.citation: Mol Endocrinol. 2006 Dec;20(12):3105-19
references.pmid: 16916939
references.citation: Mol Cell. 2008 Feb 29;29(4):465-76
references.pmid: 18313384
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6379-84
references.pmid: 10823921
references.citation: J Biol Chem. 2010 Dec 10;285(50):38743-50
references.pmid: 20956538
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17868-73
references.pmid: 17098861
references.citation: Med Sci (Paris). 2013 Oct;29(10):861-7
references.pmid: 24148124
references.citation: Expert Opin Ther Targets. 2012 Nov;16(11):1085-96
references.pmid: 22924430
references.citation: J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):3-14
references.pmid: 12650696
references.citation: Hepatology. 2009 Jul;50(1):113-21
references.pmid: 19441017
references.citation: Endocrinology. 2011 Jan;152(1):19-25
references.pmid: 21047941
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17187-92
references.pmid: 18957541
references.citation: Trends Biochem Sci. 2008 Jul;33(7):301-4
references.pmid: 18502645